Jaguar Animal Health (NASDAQ:JAGX) Stock Crosses Above 50 Day Moving Average – Should You Sell?

Jaguar Animal Health, Inc. (NASDAQ:JAGX)’s share price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.83 and traded as high as $0.9221. Jaguar Animal Health shares last traded at $0.8879, with a volume of 925,275 shares changing hands.

Wall Street Analysts Forecast Growth

JAGX has been the topic of a number of research reports. Wall Street Zen lowered shares of Jaguar Animal Health to a “strong sell” rating in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Jaguar Animal Health has an average rating of “Hold” and an average price target of $60.00.

Jaguar Animal Health Stock Up 4.0%

The company has a current ratio of 0.81, a quick ratio of 0.52 and a debt-to-equity ratio of 4.08. The firm has a market cap of $3.32 million, a PE ratio of -0.03 and a beta of 0.09. The business’s 50-day simple moving average is $0.83 and its 200 day simple moving average is $1.45.

Jaguar Animal Health’s stock is scheduled to split before the market opens on Monday, March 2nd. The 1.1-1 split was recently announced. The newly minted shares will be distributed to shareholders after the market closes on Sunday, March 1st.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.